The adult vaccines market covers immunization products designed to prevent infectious diseases in individuals aged 18 and above. These vaccines protect against conditions such as influenza, pneumococcal disease, shingles, hepatitis, HPV, meningococcal infections, and COVID-19. Market growth is driven by increasing awareness of preventive healthcare, rising prevalence of infectious diseases, expanding adult immunization programs, and government initiatives promoting vaccination coverage. Aging populations, especially in developed countries, are boosting demand as older adults are more vulnerable to infections. North America currently dominates the market due to strong healthcare infrastructure, high vaccination rates, and supportive policies, while Asia-Pacific is expected to see rapid growth with rising healthcare spending and awareness. Key challenges include vaccine hesitancy, unequal access in low- and middle-income countries, and high costs of some newer vaccines.
The global adult vaccines market size was valued at USD 40.70 billion in 2024 and is projected to grow from USD 42.06 billion in 2025 to USD 83.78 billion by 2032, exhibiting a CAGR of 10.3% during the forecast period. North America dominated the adult vaccines market with a 45.52% share in 2024, driven by strong immunization programs, rising awareness of preventable diseases, and growing government and private sector initiatives to improve vaccination coverage.
June 2025: Merck initiated the MOBILIZE-1 Phase 3 clinical trial to evaluate the efficacy, safety, and immunogenicity of V181, a single-dose dengue vaccine candidate for adults aged 18 years and above.